The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - Akeso Biopharma; AstraZeneca; GlaxoSmithKline; Mersana; MSD; Novocure; Roche; Sotio
Time course of adverse events in primary advanced or recurrent endometrial cancer treated with dostarlimab plus chemotherapy in the ENGOT-EN-6-NSGO/GOG-3031/RUBY trial.
 
Elizabeth Lokich
No Relationships to Disclose
 
Trine Lembrecht Jørgensen
No Relationships to Disclose
 
Destin Black
Stock and Other Ownership Interests - Trials365
Honoraria - GOG Partners
Consulting or Advisory Role - Intuitive Surgical; Merck; Novita Pharmaceuticals
Research Funding - Acrivon Therapeutics (Inst); AOA Diagnostics (Inst); GEICO (Inst); GlaxoSmithKline (Inst); GOG Partners (Inst); Karyopharm Therapeutics (Inst); KLUS Pharma (Inst); Merck (Inst); OncoC4 (Inst); Tesaro (Inst)
Travel, Accommodations, Expenses - Momentis surgical
 
David Cibula
No Relationships to Disclose
 
Lucy Gilbert
Honoraria - GlaxoSmithKline; Merck; Peervoice
Consulting or Advisory Role - CanariaBio; Eisai; GlaxoSmithKline; GOG Foundation; Immunogen; Kora Healthcare; Merck; Merck/Eisai
Research Funding - Alkermes (Inst); AstraZeneca (Inst); Corcept Therapeutics (Inst); Esperas Pharma (Inst); GlaxoSmithKline (Inst); GOG Foundation (Inst); Immunogen (Inst); IMV (Inst); IMV (Inst); K-Group Beta (Inst); Karyopharm Therapeutics (Inst); Merck Sharp & Dohme (Inst); Mersana (Inst); Novocure (Inst); OncoQuest (Inst); Roche (Inst); Shattuck Labs (Inst); Sutro BioPharma Inc (Inst); Tesaro (Inst)
Travel, Accommodations, Expenses - Corcept Therapeutics; EndomEra; GlaxoSmithKline; GOG Foundation; Merck; Zentalis
 
Antonella Savarese
Honoraria - CanariaBio; Eisai; GlaxoSmithKline; GOG Foundation; ImmunoGen; Kora Healthcare; Merck; Merck/Eisai
Consulting or Advisory Role - CanariaBio; Eisai; GlaxoSmithKline; GOG Foundation; Immunogen; Kora Healthcare; Merck; Merck/Eisai
Travel, Accommodations, Expenses - EndomEra; GlaxoSmithKline; GOG Foundation; Merck; Zentalis
Other Relationship - Alkermes (Inst); AstraZeneca (Inst); Clovis Oncology (Inst); Corcept Therapeutics (Inst); Esperas (Inst); GlaxoSmithKline (Inst); GOG Foundation (Inst); ImmunoGen (Inst); IMV (Inst); K-Group Beta (Inst); Karyopharm Therapeutics (Inst); Merck Sharp & Dohme (Inst); Mersana (Inst); Novocure (Inst); OncoQuest Pharmaceuticals (Inst); Roche (Inst); Shuttuck Labs (Inst); Sutro BioPharma Inc (Inst); Tesaro (Inst)
 
Matthew A. Powell
Consulting or Advisory Role - AstraZeneca; Clovis Oncology; Eisai; GlaxoSmithKline/Tesaro; GOG partners; Immunogen; Merck; Seagen; Tesaro
Research Funding - GlaxoSmithKline/Tesaro (Inst)
 
Rebecca Herbertson
No Relationships to Disclose
 
Sarah Gill
No Relationships to Disclose
 
Bradley J. Monk
Leadership - US Oncology
Honoraria - Acrivon Therapeutics; Adaptimmune; Agenus; Akeso Biopharma; Amgen; Aravive; AstraZeneca; Bayer; Clovis Oncology; Eisai; Elevar Therapeutics; EMD Serono/Merck; Genmab/Seattle Genetics; GOG Foundation; Gradalis; HenRui; ImmunoGen; Iovance Biotherapeutics; Karyopharm Therapeutics; Laekna Health Care; Merck; Mersana; Myriad Pharmaceuticals; Novartis; Novocure; OncoC4; Panavance Therapeutics; Pfizer; Pieris Pharmaceuticals; Puma Biotechnology; Regeneron; Roche/Genentech; Sorrento Therapeutics; TESARO/GSK; US Oncology; Vascular Biogenics; Verastem; Zentalis
Consulting or Advisory Role - Adaptimmune; Agenus; Akeso Biopharma; Amgen; Aravive; AstraZeneca; Bayer; Clovis Oncology; Eisai; Elevar Therapeutics; EMD Serono/Merck; Genmab/Seattle Genetics; GOG Foundation; Gradalis; Gradalis; HenRui; ImmunoGen; Iovance Biotherapeutics; Karyopharm Therapeutics; Laekna Health Care; Merck; Mersana; Myriad Pharmaceuticals; Novartis; Novocure; OncoC4; Panavance Therapeutics; Pfizer; Pieris Pharmaceuticals; Puma Biotechnology; Regeneron; Roche/Genentech; Sorrento Therapeutics; TESARO/GSK; US Oncology; Vascular Biogenics; Verastem; Zentalis
Speakers' Bureau - AstraZeneca; Clovis Oncology; Eisai; Merck; Roche/Genentech; TESARO/GSK
Research Funding - Advaxis (Inst); Amgen (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Genentech (Inst); Immunogen (Inst); Janssen (Inst); Lilly (Inst); Morphotek (Inst); Novartis (Inst); Nucana (Inst); Pfizer (Inst); Regeneron (Inst); Tesaro (Inst)
 
Nicole Nevadunsky
No Relationships to Disclose
 
Kari L. Ring
No Relationships to Disclose
 
Noelle Cloven
Consulting or Advisory Role - Aadii; GlaxoSmithKline; Kartos 2022; Novita pharmaceuticals 2023; Tarveda Therapeutics; Toray Industries; Umoja 2022; Zentalis
 
Iwona Podzielinski
No Relationships to Disclose
 
Tashanna K. N. Myers
Consulting or Advisory Role - Immunogen; Immunogen
 
Christine Dabrowski
Employment - GlaxoSmithKline
 
Shadi Stevens
Employment - GlaxoSmithKline; GlaxoSmithKline
 
Lyndsay Willmott
Consulting or Advisory Role - AstraZeneca; Immunogen; Seagen
Speakers' Bureau - AstraZeneca; Eisai; ImmunoGen; Merck; Seagen
 
Mansoor Raza Mirza
Leadership - Karyopharm Therapeutics; Sera Prognostics
Stock and Other Ownership Interests - Karyopharm Therapeutics; Sera Prognostics
Honoraria - Allarity Therapeutics; AstraZeneca; Geneos; Genmab/Seattle Genetics; GlaxoSmithKline; Merck; Mersana; Roche; Takeda; Zai Lab
Consulting or Advisory Role - AstraZeneca; Genmab; GlaxoSmithKline; Karyopharm Therapeutics; Pfizer
Research Funding - Apexigen (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Clovis Oncology (Inst); GlaxoSmithKline (Inst); Pfizer (Inst); Tesaro (Inst); Ultimovacs (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Karyopharm Therapeutics; Pfizer; Roche; SeraCare; Tesaro
Other Relationship - European Network of Gynaecological Oncologic Trials; European Society for Gynaecological Oncology; Gynecological Cancer InterGroup